Terry Pearson
Hoofd Techniek/Wetenschap/O&O bij Siscapa Assay Technologies, Inc.
Profiel
Terry W.
Pearson is currently serving as a Director at CAVA Healthcare, Inc., Director at Science Council of British Columbia, Director at Eyam Vaccines & Immunotherapeutics Ltd., and Chief Scientific Officer at Siscapa Assay Technologies, Inc. Previously, he held positions as a Director at Marker Therapeutics, Inc., Independent Director at biOasis Technologies, Inc., Independent Director at Nevis Brands, Inc., Staff Scientist-Cell Biology Division at the University of British Columbia, Professor at the University of Victoria, and Trustee at The Terry Fox Foundation.
He obtained his undergraduate and doctorate degrees from the University of British Columbia.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
inf% | 18-10-2023 | 100 000 ( inf% ) | - $ | Vandaag |
Actieve functies van Terry Pearson
| Bedrijven | Functie | Begin |
|---|---|---|
| Science Council of British Columbia | Directeur/Bestuurslid | 01-09-2010 |
CAVA Healthcare, Inc.
 CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | Directeur/Bestuurslid | - |
Siscapa Assay Technologies, Inc.
 Siscapa Assay Technologies, Inc. BiotechnologyHealth Technology Siscapa Assay Technologies, Inc. provides products and services for precise quantitation of protein biomarkers, drugs, and drug targets using immuno-affinity mass spectrometry. Siscapa assays are used in clinical diagnostics and pharma R&D for particularly demanding applications, and in biomarker panels to characterize changes in health, disease, and treatment in longitudinal user-collected dried blood microsamples. Siscapa immuno-affinity mass spectrometry assays for targeted protein quantitation can be developed more quickly than typical ELISA immunoassays since they require only a single specific antibody and provide absolute target specificity because of the MS detection. Because Siscapa assays do not interact with one another, these assays can be freely assembled in panels for various applications. The American company was founded by N. Leigh Anderson, who has been the CEO since incorporation. | Hoofd Techniek/Wetenschap/O&O | - |
| Eyam Vaccines & Immunotherapeutics Ltd. | Directeur/Bestuurslid | 10-01-2022 |
Eerdere bekende functies van Terry Pearson
| Bedrijven | Functie | Einde |
|---|---|---|
| BIOASIS TECHNOLOGIES INC. | Directeur/Bestuurslid | 21-09-2017 |
| MARKER THERAPEUTICS, INC. | Directeur/Bestuurslid | 05-12-2005 |
| University of British Columbia | Corporate Officer/Principal | - |
| NEVIS BRANDS INC. | Directeur/Bestuurslid | - |
| University of Victoria | Corporate Officer/Principal | - |
Opleiding van Terry Pearson
| University of British Columbia | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| MARKER THERAPEUTICS, INC. | Health Technology |
| BIOASIS TECHNOLOGIES INC. | Health Technology |
| NEVIS BRANDS INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Siscapa Assay Technologies, Inc.
Siscapa Assay Technologies, Inc. BiotechnologyHealth Technology Siscapa Assay Technologies, Inc. provides products and services for precise quantitation of protein biomarkers, drugs, and drug targets using immuno-affinity mass spectrometry. Siscapa assays are used in clinical diagnostics and pharma R&D for particularly demanding applications, and in biomarker panels to characterize changes in health, disease, and treatment in longitudinal user-collected dried blood microsamples. Siscapa immuno-affinity mass spectrometry assays for targeted protein quantitation can be developed more quickly than typical ELISA immunoassays since they require only a single specific antibody and provide absolute target specificity because of the MS detection. Because Siscapa assays do not interact with one another, these assays can be freely assembled in panels for various applications. The American company was founded by N. Leigh Anderson, who has been the CEO since incorporation. | Health Technology |
CAVA Healthcare, Inc.
CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | Consumer Non-Durables |
| The Terry Fox Foundation | |
| Science Council of British Columbia | |
| Eyam Vaccines & Immunotherapeutics Ltd. |
